

Title (en)
CONSTITUTIVE AND INDUCIBLE EPIDERMAL VECTOR SYSTEMS.

Title (de)
KONSTITUTIVES UND INDUZIEBARES VEKTORSYSTEM FÜR DIE EPIDERMIS.

Title (fr)
SYSTEMES DE VECTEURS EPIDERMiques CONSTITUTIFS ET INDUCTIFS.

Publication
EP 0644933 A1 19950329 (EN)

Application
EP 93910875 A 19930428

Priority
• US 9303993 W 19930428
• US 87628692 A 19920430

Abstract (en)
[origin: WO9322431A1] A loricrin constitutive vector for efficient expression of a nucleic acid sequence in epidermal cells comprising the 5' flanking region of the loricrin gene, said flanking region containing a TATA box, a cap site and a first intron and intron/exon boundary all in appropriate sequential and positional relationship for expression of a nucleic acid cassette, a 3' flanking sequence of the loricrin gene and a linker containing a unique restriction endonuclease site at the location of the start and stop codon. Said linker connecting the 5' flanking region to the 3' flanking sequence and said linker further providing a position for inserting the cassette. The cassette contains the specific nucleic acid sequence to be expressed. Also, there is a keratin K6 inducible vector for regulating expression of a nucleic acid sequence in epidermal cells comprising the 5' flanking region of the keratin K6 gene, said flanking region including the TATA box, a cap site and the first intron and intron/exon boundary all in sequential and positional relationship for expression of a nucleic acid cassette, a 3' flanking sequence of the keratin K6 gene, and a polylinker having a plurality of restriction endonuclease sites. The polylinker connects the 5' flanking region to the 3' flanking sequence and further provides a position for insertion of the cassette. The keratin K6 and loricrin vectors can be further regulated by the addition of a Vitamin D regulatory element. The vectors can be used in a bioreactor for generating a variety of products including proteins, polypeptides or antisense RNAs. The vectors can also be used for gene therapy in treatment of a variety of diseases in animals and humans including wound healing, surgical incisions, skin ulcers, psoriasis and skin cancer, and in vaccination.

IPC 1-7
C12N 15/00; **C12N 15/12**; **C12N 15/63**; **C12N 15/64**; **C12N 15/85**; **C12M 3/00**; **C12M 3/02**; **C12M 3/04**; **A61K 31/70**

IPC 8 full level
A01K 67/027 (2006.01); **A61K 31/70** (2006.01); **A61K 48/00** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07H 21/04** (2006.01); **C07K 14/47** (2006.01); **C12M 3/00** (2006.01); **C12N 15/09** (2006.01); **C12N 15/85** (2006.01)

CPC (source: EP)
A61P 35/00 (2017.12); **A61P 43/00** (2017.12); **C07K 14/47** (2013.01); **C12N 15/85** (2013.01); **A61K 48/00** (2013.01); **C12N 2830/005** (2013.01); **C12N 2830/008** (2013.01); **C12N 2830/32** (2013.01); **C12N 2830/42** (2013.01); **C12N 2830/85** (2013.01)

Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9322431 A1 19931111; AU 4221393 A 19931129; AU 669713 B2 19960620; CA 2134670 A1 19931111; EP 0644933 A1 19950329; EP 0644933 A4 19970625; JP H08501202 A 19960213

DOCDB simple family (application)
US 9303993 W 19930428; AU 4221393 A 19930428; CA 2134670 A 19930428; EP 93910875 A 19930428; JP 51948793 A 19930428